Marker Therapeutics Inc (MRKR) is a Healthcare · Biotechnology company listed on NASDAQ. Price $1.18 (+0.00%), Market cap $0.02B, 52-week low–high $0.85 ~ $2.19.
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, develops and commercializes T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications in the United States. The company's multi antigen recognizing (MAR)-T cell therapy technology is based on the selective expansion of non-engineered tumor-specific T cells that recognize tumor-associated antigens and kill tumor cells expressing those targets. It develops MT-601, which is in Phase 1 trials for the treatment of lymphoma and pancreatic cancer; and MT-401-OTS, which is in a Phase 1 trial for the treatment of acute myeloid leukemia and myelodysplastic syndromes. The company was form
Financial statements, price targets, institutional (13F) holdings and related news for Marker Therapeutics Inc are updated in real time on BlackAll Trade.
Marker Therapeutics Inc trades at $1.18 (+0.00%). Real-time quotes and charts are available on BlackAll Trade.
Marker Therapeutics Inc has a market cap of about $0.02B.
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, develops and commercializes T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indication